WeChat Mini Program
Old Version Features

Efficacy of Pembrolizumab Vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status

Walid Shalata,Natalie Maimon Rabinovich,Abed Agbarya,Alexander Yakobson,Yulia Dudnik,Ashraf Abu Jama,Ahron Yehonatan Cohen,Sondos Shalata, Ahmad Abu Hamed, Tahel Ilan Ber, Oshri Machluf, Gal Shoham Levin,Amichay Meirovitz

CANCERS（2024）

Cited 1|Views23
Key words
non-small cell lung cancer (NSCLC),PDL-1,TMB,real-world data,immune checkpoint inhibitor,pembrolizumab,nivolumab,ipilimumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined